EKF Diagnostics Holdings Plc is a vitro diagnostics company, which engages in the designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan and currently employs 304 full-time employees. The company went IPO on 2002-06-05. The firm develops and produces in-vitro diagnostic (IVD) devices and tests designed for use at or near the patient’s location. The company provides a suite of products for diabetes management, including glucose monitoring systems and associated consumables. The company offers devices, supplies, and consumables for measuring hemoglobin levels, including tools for detecting hemoglobin variants. The company also develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and biomaterials. The company provides precision fermentation, custom bioprocessing, and contract manufacturing services for pharmaceuticals and other biological products. The company supplies beta-hydroxybutyrate (HB) products used in ketone detection to support the diagnosis of diabetic ketoacidosis and other clinical conditions.
Follow-Up Questions
Who is the CEO of EKF Diagnostics Holdings PLC?
Mr. Gavin Jones is the Chief Executive Officer of EKF Diagnostics Holdings PLC, joining the firm since 2025.
What is the price performance of EKDHF stock?
The current price of EKDHF is $0.4, it has decreased 0% in the last trading day.
What are the primary business themes or industries for EKF Diagnostics Holdings PLC?
EKF Diagnostics Holdings PLC belongs to Health Care industry and the sector is Health Care
What is EKF Diagnostics Holdings PLC market cap?
EKF Diagnostics Holdings PLC's current market cap is $179.6M
Is EKF Diagnostics Holdings PLC a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for EKF Diagnostics Holdings PLC, including 4 strong buy, 6 buy, 1 hold, 0 sell, and 4 strong sell
